Cargando…
Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis
Aim: Our main objectives were to compare the effects of Rejuveinix (RJX), dexamethasone (DEX) and their combination on the severity of sepsis and survival outcome in an animal model of fatal sepsis. Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory...
Autores principales: | Uckun, Fatih M, Saeed, Muhammad, Awili, Mustafa, Ozercan, Ibrahim H, Qazi, Sanjive, Lee, Cynthia, Shibli, Adeel, Skolnick, Alan W, Prusmack, Alonso, Varon, Joseph, Barrera, Cesar IP, Orhan, Cemal, Volk, Michael, Sahin, Kazim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443789/ https://www.ncbi.nlm.nih.gov/pubmed/36052743 http://dx.doi.org/10.2217/fmb-2022-0044 |
Ejemplares similares
-
Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi‐Organ Failure
por: Uckun, Fatih M., et al.
Publicado: (2020) -
RJX Improves Wound Healing in Diabetic Rats
por: Uckun, Fatih M., et al.
Publicado: (2022) -
Clinical Impact Potential of Supplemental Nutrients as Adjuncts of Therapy in High-Risk COVID-19 for Obese Patients
por: Sahin, Emre, et al.
Publicado: (2020) -
SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia
por: Uckun, Fatih M., et al.
Publicado: (2014) -
Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas
por: Uckun, Fatih M., et al.
Publicado: (2018)